IL248704A0 - טיפול משולב באימונותרפיה ורדיותרפיה לטיפול בסוגי סרטן המבטאים her-2 - Google Patents

טיפול משולב באימונותרפיה ורדיותרפיה לטיפול בסוגי סרטן המבטאים her-2

Info

Publication number
IL248704A0
IL248704A0 IL248704A IL24870416A IL248704A0 IL 248704 A0 IL248704 A0 IL 248704A0 IL 248704 A IL248704 A IL 248704A IL 24870416 A IL24870416 A IL 24870416A IL 248704 A0 IL248704 A0 IL 248704A0
Authority
IL
Israel
Prior art keywords
radiotherapy
treatment
positive cancers
immuno therapy
combination
Prior art date
Application number
IL248704A
Other languages
English (en)
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/268,436 external-priority patent/US20140234370A1/en
Priority claimed from PCT/US2015/017559 external-priority patent/WO2015130810A2/en
Priority claimed from US14/669,629 external-priority patent/US10016617B2/en
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of IL248704A0 publication Critical patent/IL248704A0/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL248704A 2014-05-02 2016-11-02 טיפול משולב באימונותרפיה ורדיותרפיה לטיפול בסוגי סרטן המבטאים her-2 IL248704A0 (he)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14/268,436 US20140234370A1 (en) 2009-11-11 2014-05-02 Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
US201462076411P 2014-11-06 2014-11-06
PCT/US2015/017559 WO2015130810A2 (en) 2014-02-25 2015-02-25 Compositions and methods for the treatment of her2/neu over-expressing tumors
US14/669,629 US10016617B2 (en) 2009-11-11 2015-03-26 Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
PCT/US2015/024048 WO2015167748A1 (en) 2014-05-02 2015-04-02 Combination immuno therapy and radiotherapy for the treatment of her-2-positive cancers

Publications (1)

Publication Number Publication Date
IL248704A0 true IL248704A0 (he) 2017-01-31

Family

ID=54359144

Family Applications (1)

Application Number Title Priority Date Filing Date
IL248704A IL248704A0 (he) 2014-05-02 2016-11-02 טיפול משולב באימונותרפיה ורדיותרפיה לטיפול בסוגי סרטן המבטאים her-2

Country Status (11)

Country Link
EP (1) EP3137107A4 (he)
JP (1) JP2017514904A (he)
KR (1) KR20170002552A (he)
CN (1) CN106794234A (he)
AU (1) AU2015253737A1 (he)
CA (1) CA2947677A1 (he)
IL (1) IL248704A0 (he)
MA (1) MA39942A (he)
MX (1) MX2016014367A (he)
SG (1) SG11201609135VA (he)
WO (1) WO2015167748A1 (he)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
EP2683400A4 (en) 2011-03-11 2014-09-17 Advaxis ADJUVANZIA ON LISTERIA BASE
SG10201700392UA (en) 2012-03-12 2017-03-30 Advaxis Inc Suppressor cell function inhibition following listeria vaccine treatment
SG11201606677XA (en) 2014-02-18 2016-09-29 Advaxis Inc Biomarker directed multi-target immunotherapy
SG11201608820WA (en) 2014-04-24 2016-11-29 Advaxis Inc Recombinant listeria vaccine strains and methods of producing the same
MA41644A (fr) 2015-03-03 2018-01-09 Advaxis Inc Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
US20190134174A1 (en) * 2016-06-03 2019-05-09 Etubics Corporation Compositions and methods for tumor vaccination and immunotherapy involving her2/neu
JP7197481B2 (ja) 2016-11-30 2022-12-27 アドバクシス， インコーポレイテッド 反復性がん突然変異を標的とする免疫原性組成物およびその使用の方法
WO2019060115A1 (en) 2017-09-19 2019-03-28 Advaxis, Inc. COMPOSITIONS AND METHODS FOR LYOPHILIZATION OF BACTERIA OR LISTERIA STRAINS

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US6855320B2 (en) 2000-03-29 2005-02-15 The Trustees Of The University Of Pennsylvania Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity
US7432304B2 (en) * 2001-05-30 2008-10-07 The Regents Of The University Of Michigan Small molecule antagonists of Bcl-2 family proteins
AU2004281834A1 (en) * 2003-10-15 2005-04-28 Cerus Corporation Listeria-based EphA2 vaccines
US9017660B2 (en) * 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
EP2498808A4 (en) * 2009-11-11 2014-01-08 Advaxis COMPOSITIONS AND METHOD FOR PREVENTING FLUID MUTATIONS IN THE TREATMENT OF TUMORS WITH HER2 / NEW OVEREXPRESSION
US20110223187A1 (en) * 2010-02-15 2011-09-15 Vafa Shahabi Live listeria-based vaccines for central nervous system therapy
CN102947452A (zh) * 2010-05-23 2013-02-27 艾杜罗生物科技公司 使用用于癌症的辅佐治疗的李斯特菌属的方法和组合物

Also Published As

Publication number Publication date
CA2947677A1 (en) 2015-11-05
KR20170002552A (ko) 2017-01-06
CN106794234A (zh) 2017-05-31
JP2017514904A (ja) 2017-06-08
MA39942A (fr) 2017-03-08
EP3137107A4 (en) 2018-01-17
MX2016014367A (es) 2017-06-30
AU2015253737A1 (en) 2016-12-22
WO2015167748A1 (en) 2015-11-05
SG11201609135VA (en) 2016-11-29
EP3137107A1 (en) 2017-03-08

Similar Documents

Publication Publication Date Title
IL297418B1 (he) טיפול חיסוני משולב וטיפול בקרת ציטוקין לטיפול בסרטן
IL291844B1 (he) טיפול משולב smc לטיפול בסרטן
IL290149A (he) טיפול משולב לטיפול בסרטן
IL261008A (he) טיפול חיסוני משולב וטיפול בקרת ציטוקין לטיפול בסרטן
IL272740A (he) טיפול חיסוני משולב וטיפול בקרת ציטוקין לטיפול בסרטן
GB201719076D0 (en) Particles for the treatment of cancer in combination with radiotherapy
HK1247129A1 (zh) 治療癌症的聯合療法
IL267795A (he) טיפול משולב לטיפול בסרטן
HK1251475A1 (zh) 用於癌症治療的聯合療法
SG11201700079VA (en) Combination therapy compositions and methods for treating cancers
IL248704A0 (he) טיפול משולב באימונותרפיה ורדיותרפיה לטיפול בסוגי סרטן המבטאים her-2
IL274837B1 (he) טיפול משולב לטיפול בסרטן
LT3622953T (lt) Kombinuotas vėžio gydymas
IL266993A (he) תרפיה משולבת לטיפול בסרטן
IL275517A (he) שיטות וטיפול מצרפי בסרטן
IL264589A (he) טיפול משולב לטיפול בסרטן הלבלב
IL258494A (he) טיפול משולב רציונלי לטיפול בסרטן
IL253642A0 (he) טיפול משולב לטיפול בסרטן
GB201704474D0 (en) Combination therapy for treatment of cancer
GB201717004D0 (en) Methods of cancer therapy
GB201711769D0 (en) Methods of cancer therapy
GB201416605D0 (en) Combination therapy to reduce the risk of and to treat cancer